肺癌筛查

Q4 Medicine Revue des Maladies Respiratoires Actualites Pub Date : 2024-10-01 DOI:10.1016/S1877-1203(24)00072-7

S. Couraud , E. Grolleau , B. Milleron , V. Gounant , O. Leleu

{"title":"肺癌筛查","authors":"S. Couraud , E. Grolleau , B. Milleron , V. Gounant , O. Leleu","doi":"10.1016/S1877-1203(24)00072-7","DOIUrl":null,"url":null,"abstract":"<div><div>Several randomized trials have demonstrated that a low-dose thoracic CT scan screening strategy without contrast injection reduces both lung cancer mortality and overall mortality in a high-risk population. In France and Europe, several scientific societies have advocated for this screening to be performed in eligible individuals. In France, the eligibility criteria are: age between 50 and 75 years, a smoking history of more than 20 pack-years, either current smokers or those who have quit within the last 15 years. A pilot national initiative is expected to begin in 2025 in the form of a clinical trial. This trial will assess the feasibility of nationwide screening and address major questions such as the role of biomarkers, optimization of eligible population selection, and the contribution of Artificial Intelligence. 1877-1203/© 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>","PeriodicalId":53645,"journal":{"name":"Revue des Maladies Respiratoires Actualites","volume":"16 2","pages":"Pages 2S27-2S33"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Le dépistage du cancer du poumon\",\"authors\":\"S. Couraud , E. Grolleau , B. Milleron , V. Gounant , O. Leleu\",\"doi\":\"10.1016/S1877-1203(24)00072-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Several randomized trials have demonstrated that a low-dose thoracic CT scan screening strategy without contrast injection reduces both lung cancer mortality and overall mortality in a high-risk population. In France and Europe, several scientific societies have advocated for this screening to be performed in eligible individuals. In France, the eligibility criteria are: age between 50 and 75 years, a smoking history of more than 20 pack-years, either current smokers or those who have quit within the last 15 years. A pilot national initiative is expected to begin in 2025 in the form of a clinical trial. This trial will assess the feasibility of nationwide screening and address major questions such as the role of biomarkers, optimization of eligible population selection, and the contribution of Artificial Intelligence. 1877-1203/© 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.</div></div>\",\"PeriodicalId\":53645,\"journal\":{\"name\":\"Revue des Maladies Respiratoires Actualites\",\"volume\":\"16 2\",\"pages\":\"Pages 2S27-2S33\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue des Maladies Respiratoires Actualites\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877120324000727\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue des Maladies Respiratoires Actualites","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877120324000727","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

多项随机试验表明，不注射造影剂的低剂量胸部 CT 扫描筛查策略可降低高危人群的肺癌死亡率和总死亡率。在法国和欧洲，一些科学协会倡导对符合条件的人进行这种筛查。在法国，筛查的资格标准是：年龄在 50 岁至 75 岁之间，吸烟史超过 20 包年，既可以是目前的吸烟者，也可以是在过去 15 年内戒烟的人。预计将于 2025 年以临床试验的形式在全国范围内开展试点工作。该试验将评估全国范围内筛查的可行性，并解决生物标志物的作用、合格人群选择的优化以及人工智能的贡献等重大问题。1877-1203/© 2024 splf.由 Elsevier Masson SAS 出版。保留所有权利。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Le dépistage du cancer du poumon

Several randomized trials have demonstrated that a low-dose thoracic CT scan screening strategy without contrast injection reduces both lung cancer mortality and overall mortality in a high-risk population. In France and Europe, several scientific societies have advocated for this screening to be performed in eligible individuals. In France, the eligibility criteria are: age between 50 and 75 years, a smoking history of more than 20 pack-years, either current smokers or those who have quit within the last 15 years. A pilot national initiative is expected to begin in 2025 in the form of a clinical trial. This trial will assess the feasibility of nationwide screening and address major questions such as the role of biomarkers, optimization of eligible population selection, and the contribution of Artificial Intelligence. 1877-1203/© 2024 SPLF. Published by Elsevier Masson SAS. All rights reserved.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助